The liquid formulation of Azithromycin, a critical antibiotic for children, is facing a shortage due to increased global demand, spurred by a resurgence of respiratory illnesses like pertussis. Expected to last until late November, this shortage poses significant challenges. Alternatives such as clarithromycin and doxycycline are available but with drawbacks. Temporary solutions include an overseas brand of azithromycin liquid formulation and transitioning children to tablets.